Home › Trials › NCT04460950

Evaluating familial cases of blood cancers in patients with myeloid neoplasms

A Retrospective and Prospective Multicentre Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms (AML/MDS)

Observational Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04460950

This study looks at families with a history of blood cancers to see how often people with Acute Myeloid Leukemia or Myelodysplastic Syndromes also have relatives affected by these diseases.

Quick facts

Study typeObservational
Enrollment237 (estimated)
Ages18 Years and up
SexAll
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto Academic / other
Locations27 sites (Alessandria and 26 other locations)
Trial IDNCT04460950 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the incidence of familial Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) in patients diagnosed with these conditions between January 2014 and December 2022. It will collect clinical information from multiple centers, focusing on patients who have at least one relative affected by hematologic neoplasms or other cancers diagnosed at a young age. The study will follow participants until December 2023 to gather comprehensive data on familial patterns of these diseases. No interventions will be administered, as the study is purely observational.

Who should consider this trial

Good fit: Ideal candidates include adults over 18 years old diagnosed with AML or MDS who have a family history of hematologic malignancies or solid tumors diagnosed before age 40.

Not a fit: Patients without a family history of myeloid neoplasms or related cancers may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of the genetic factors contributing to familial AML and MDS, potentially leading to improved screening and prevention strategies.

How similar studies have performed: While this approach is observational, similar studies have successfully identified familial patterns in other cancers, suggesting potential for valuable insights in this context.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patient age \> 18 years old
* Diagnosis of AML or MDSs from January 2014 to December 2022
* Suspected familiarity for myeloid neoplasm: at least one family member of first or second degree affected by myeloid neoplasm or other hematological malignancy, or by solid tumors with onset at age \< 40 years or presence of signs, symptoms or laboratory tests compatible with one of the known syndromes with germinal susceptibility to AML/MDSs
* Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion Criteria:

* none

Where this trial is running

Alessandria and 26 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Acute Myeloid LeukemiaFamilial Acute Myeloid LeukemiaMyelodysplastic Syndromes
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.